Short answer: there isn’t a straightforward, one-number comparison. There are no direct head-to-head trials comparing Cosentyx (secukinumab) with Humira (adalimumab) across all indications, and “success rate” depends on the disease, the endpoint (e.g., PASI75, ACR20, ASAS40), and the dosing used. Indirect comparisons are therefore imperfect.
Here’s a condition-by-condition, high-level view of how their trial results tend to look:
- Plaque psoriasis
- Cosentyx: In pivotal psoriasis trials, secukinumab produced strong skin-clearance results (high PASI75 rates) by about Week 12, often in the higher end of PASI75/90 ranges depending on dose.
- Humira: Adalimumab also yields substantial PASI75 responses, but cross-trial differences make exact ranking hard.
- Bottom line: Both can achieve substantial skin clearance; some indirect comparisons suggest secukinumab can lead to higher PASI responses at early timepoints in some trials, but you can’t rely on this to declare a clear winner.
- Psoriatic arthritis
- Cosentyx: ACR20/50/70 responses observed in pivotal PsA trials; magnitude is meaningful and clinically relevant.
- Humira: Also yields strong ACR responses in PsA.
- Bottom line: Both are effective; direct head-to-head data are not available.
- Ankylosing spondylitis / axial spondyloarthritis
- Cosentyx: ASAS20/40 responses observed in trials.
- Humira: Also shows robust ASAS responses.
- Bottom line: Efficacy is substantial for both; exact comparative numbers aren’t directly comparable across trials.
- Crohn’s disease and ulcerative colitis
- Humira: Well-established efficacy in Crohn’s disease (and UC).
- Cosentyx: Not proven effective in Crohn’s disease; not approved for Crohn’s or UC.
- Bottom line: Humira has a clear success track record here; Cosentyx does not.
- Uveitis
- Humira: Strong, well-supported evidence for noninfectious uveitis.
- Cosentyx: Data are more limited; less clear evidence.
- Bottom line: Humira has the stronger, more established uveitis evidence.
What this means for you
- If your target condition is psoriasis, both drugs are highly effective; indirect comparisons sometimes suggest secukinumab may achieve higher skin-clearance rates earlier in some trials, but the differences aren’t definitive due to trial design and populations.
- If you’re considering Crohn’s disease or UC, Humira has proven efficacy; Cosentyx has not demonstrated benefit in Crohn’s and isn’t approved for these diseases.
- For PsA or axial spondyloarthritis, both drugs provide meaningful benefit; direct comparisons aren’t available.
- Safety profiles differ in ways that may matter for individual patients (e.g., infection risks, TB reactivation risk with TNF inhibitors like Humira; newer IL-17 inhibitors have their own safety considerations). A clinician can weigh these along with efficacy.
If you tell me which condition you care about (psoriasis, PsA, AS, Crohn’s/UC, uveitis, etc.), I can summarize the pivotal trial endpoints and typical response rates for Cosentyx and Humira in that specific setting, and point out where data are strongest or weakest.